147 related articles for article (PubMed ID: 23919745)
1. Assessment of nutritional status in cancer--the relationship between body composition and pharmacokinetics.
Prado CM; Maia YL; Ormsbee M; Sawyer MB; Baracos VE
Anticancer Agents Med Chem; 2013 Oct; 13(8):1197-203. PubMed ID: 23919745
[TBL] [Abstract][Full Text] [Related]
2. Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.
Huillard O; Boissier E; Blanchet B; Thomas-Schoemann A; Cessot A; Boudou-Rouquette P; Durand JP; Coriat R; Giroux J; Alexandre J; Vidal M; Goldwasser F
Expert Opin Drug Saf; 2014 May; 13(5):663-73. PubMed ID: 24693873
[TBL] [Abstract][Full Text] [Related]
3. Eicosapentaenoic acid in cancer improves body composition and modulates metabolism.
Pappalardo G; Almeida A; Ravasco P
Nutrition; 2015 Apr; 31(4):549-55. PubMed ID: 25770317
[TBL] [Abstract][Full Text] [Related]
4. Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial.
Awada A; Gil T; Whenham N; Van Hamme J; Besse-Hammer T; Brendel E; Delesen H; Joosten MC; Lathia CD; Loembé BA; Piccart-Ghebart M; Hendlisz A
J Clin Pharmacol; 2011 Dec; 51(12):1674-84. PubMed ID: 21209247
[TBL] [Abstract][Full Text] [Related]
5. A review of body composition and pharmacokinetics in oncology.
Hopkins JJ; Sawyer MB
Expert Rev Clin Pharmacol; 2017 Sep; 10(9):947-956. PubMed ID: 28649898
[TBL] [Abstract][Full Text] [Related]
6. Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact.
Prado CM; Cushen SJ; Orsso CE; Ryan AM
Proc Nutr Soc; 2016 May; 75(2):188-98. PubMed ID: 26743210
[TBL] [Abstract][Full Text] [Related]
7. Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review.
Leonetti A; Bersanelli M; Castagneto B; Masini C; Di Meglio G; Pellegrino B; Buti S
Clin Genitourin Cancer; 2016 Aug; 14(4):277-83. PubMed ID: 26899142
[TBL] [Abstract][Full Text] [Related]
8. Cancer-associated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later.
Ryan AM; Power DG; Daly L; Cushen SJ; Ní Bhuachalla Ē; Prado CM
Proc Nutr Soc; 2016 May; 75(2):199-211. PubMed ID: 26786393
[TBL] [Abstract][Full Text] [Related]
9. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
Simonelli M; Zucali PA; Lorenzi E; Rubino L; De Vincenzo F; De Sanctis R; Perrino M; Mancini L; Di Tommaso L; Rimassa L; Masci G; Zuradelli M; Suter MB; Bertossi M; Fattuzzo G; Giordano L; Roncalli MG; Santoro A
Eur J Cancer; 2013 Mar; 49(5):989-98. PubMed ID: 23146956
[TBL] [Abstract][Full Text] [Related]
10. Review of nutritional status, body composition, and effects of antineoplastic drug disposition.
Wiernikowski JT; Bernhardt MB
Pediatr Blood Cancer; 2020 Jun; 67 Suppl 3():e28207. PubMed ID: 32083372
[TBL] [Abstract][Full Text] [Related]
11. The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
García-Alfonso P; Grande E; Polo E; Afonso R; Reina JJ; Jorge M; Campos JM; Martínez V; Angeles C; Montagut C
Angiogenesis; 2014 Oct; 17(4):805-21. PubMed ID: 24793846
[TBL] [Abstract][Full Text] [Related]
12. Biological evaluation of a novel sorafenib analogue, t-CUPM.
Wecksler AT; Hwang SH; Liu JY; Wettersten HI; Morisseau C; Wu J; Weiss RH; Hammock BD
Cancer Chemother Pharmacol; 2015 Jan; 75(1):161-71. PubMed ID: 25413440
[TBL] [Abstract][Full Text] [Related]
13. Impact of Body Weight and Body Composition on Ovarian Cancer Prognosis.
Purcell SA; Elliott SA; Kroenke CH; Sawyer MB; Prado CM
Curr Oncol Rep; 2016 Feb; 18(2):8. PubMed ID: 26769113
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer.
Makielski RJ; Lubner SJ; Mulkerin DL; Traynor AM; Groteluschen D; Eickhoff J; LoConte NK
Cancer Chemother Pharmacol; 2015 Aug; 76(2):317-23. PubMed ID: 26068189
[TBL] [Abstract][Full Text] [Related]
15. Transarterial Chemoembolization Using Sorafenib in a Rabbit VX2 Liver Tumor Model: Pharmacokinetics and Antitumor Effect.
Kim GM; Kim MD; Kim do Y; Kim SH; Won JY; Park SI; Lee do Y; Shin W; Shin M
J Vasc Interv Radiol; 2016 Jul; 27(7):1086-92. PubMed ID: 27179404
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice.
Edginton AN; Zimmerman EI; Vasilyeva A; Baker SD; Panetta JC
Cancer Chemother Pharmacol; 2016 May; 77(5):1039-52. PubMed ID: 27053087
[TBL] [Abstract][Full Text] [Related]
17. PharmGKB summary: sorafenib pathways.
Gong L; Giacomini MM; Giacomini C; Maitland ML; Altman RB; Klein TE
Pharmacogenet Genomics; 2017 Jun; 27(6):240-246. PubMed ID: 28362716
[No Abstract] [Full Text] [Related]
18. Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.
Yoon EL; Yeon JE; Lee HJ; Suh SJ; Lee SJ; Kang SH; Kang K; Yoo YJ; Kim JH; Yim HJ; Byun KS
J Clin Gastroenterol; 2014 Mar; 48(3):e22-9. PubMed ID: 24045282
[TBL] [Abstract][Full Text] [Related]
19. Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib.
Tlemsani C; Huillard O; Arrondeau J; Boudou-Rouquette P; Cessot A; Blanchet B; Thomas-Schoemann A; Coriat R; Durand JP; Giroux J; Alexandre J; Goldwasser F
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):785-94. PubMed ID: 25809423
[TBL] [Abstract][Full Text] [Related]
20. Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08-20.
Patt Y; Rojas-Hernandez C; Fekrazad HM; Bansal P; Lee FC
Oncologist; 2017 Oct; 22(10):1158-e116. PubMed ID: 28687627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
